Edmond DE Rothschild Holding S.A. Acquires Shares of 252,600 Tandem Diabetes Care, Inc. $TNDM

Key Points

• Edmond DE Rothschild Holding S.A. acquired 252,600 shares of Tandem Diabetes Care, valued at approximately $4,840,000, representing about 0.38% ownership of the company.
• A significant increase in holdings was reported by Jacobs Levy Equity Management Inc., which grew its stake by 189% in the last quarter, now owning over 1.6 million shares worth roughly $59.8 million.
• Analysts have downgraded Tandem Diabetes Care, with Wall Street Zen changing their rating from "hold" to "sell" and a consensus price target decrease from $45 to $22.47.

Edmond DE Rothschild Holding S.A. acquired a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 252,600 shares of the medical device company's stock, valued at approximately $4,840,000. Edmond DE Rothschild Holding S.A. owned about 0.38% of Tandem Diabetes Care as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Assetmark Inc. increased its stake in shares of Tandem Diabetes Care by 42.9% in the first quarter. Assetmark Inc. now owns 1,750 shares of the medical device company's stock worth $34,000 after purchasing an additional 525 shares in the last quarter. NBC Securities Inc. bought a new position in shares of Tandem Diabetes Care in the first quarter valued at approximately $37,000. Brooklyn Investment Group lifted its position in Tandem Diabetes Care by 417.8% during the first quarter. Brooklyn Investment Group now owns 3,397 shares of the medical device company's stock valued at $65,000 after purchasing an additional 2,741 shares during the last quarter. State of Wyoming lifted its position in Tandem Diabetes Care by 49.1% during the first quarter. State of Wyoming now owns 4,467 shares of the medical device company's stock valued at $86,000 after purchasing an additional 1,471 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Tandem Diabetes Care by 102.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,902 shares of the medical device company's stock valued at $141,000 after purchasing an additional 1,977 shares during the last quarter.

Insider Transactions at Tandem Diabetes Care

In related news, CFO Leigh Vosseller bought 13,720 shares of the stock in a transaction on Friday, August 8th. The shares were acquired at an average price of $10.89 per share, for a total transaction of $149,410.80. Following the purchase, the chief financial officer owned 25,580 shares of the company's stock, valued at approximately $278,566.20. The trade was a 115.68% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John F. Sheridan bought 10,000 shares of the stock in a transaction on Monday, August 11th. The shares were bought at an average price of $10.23 per share, for a total transaction of $102,300.00. Following the purchase, the chief executive officer directly owned 106,327 shares in the company, valued at approximately $1,087,725.21. This trade represents a 10.38% increase in their position. The disclosure for this purchase can be found here. Insiders own 1.90% of the company's stock.

Analysts Set New Price Targets

TNDM has been the topic of several research reports. Lake Street Capital downgraded shares of Tandem Diabetes Care from a "buy" rating to a "hold" rating and decreased their price target for the stock from $75.00 to $12.00 in a research note on Monday, August 11th. UBS Group decreased their price target on shares of Tandem Diabetes Care from $20.00 to $17.00 and set a "neutral" rating on the stock in a research note on Thursday, August 7th. Canaccord Genuity Group set a $24.00 price target on shares of Tandem Diabetes Care and gave the stock a "buy" rating in a research note on Thursday, August 7th. Barclays decreased their price target on shares of Tandem Diabetes Care from $53.00 to $51.00 and set an "overweight" rating on the stock in a research note on Friday, August 8th. Finally, Wall Street Zen downgraded shares of Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research note on Saturday, June 21st. Four research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $22.47.

Tandem Diabetes Care Stock Up 1.5%

Tandem Diabetes Care stock traded up $0.19 during mid-day trading on Friday, reaching $12.58. The stock had a trading volume of 1,612,162 shares, compared to its average volume of 2,043,510. The company has a market capitalization of $850.03 million, a price-to-earnings ratio of -4.07 and a beta of 1.45. The company has a 50-day moving average price of $14.07 and a two-hundred day moving average price of $18.09. Tandem Diabetes Care, Inc. has a one year low of $9.98 and a one year high of $47.60. The company has a debt-to-equity ratio of 2.32, a current ratio of 2.44 and a quick ratio of 1.88.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical device company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.08). The firm had revenue of $240.68 million during the quarter, compared to the consensus estimate of $238.39 million. Tandem Diabetes Care had a negative return on equity of 65.40% and a negative net margin of 20.51%.The business's revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.47) EPS. On average, analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.